Log In
BCIQ
Print this Print this
 

Vesimune (TMX-101)

  Manage Alerts
Collapse Summary General Information
Company UroGen Pharma Ltd.
DescriptionToll-like receptor 7 (TLR7) agonist
Molecular Target Toll-like receptor 7 (TLR7)
Mechanism of ActionToll-like receptor 7 (TLR7) agonist
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationBladder cancer
Indication DetailsTreat carcinoma in situ (CIS) of the bladder; Treat non-muscle invasive bladder cancer
Regulatory Designation U.S. - Orphan Drug (Treat carcinoma in situ (CIS) of the bladder)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/13/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today